Trial of Extended Release Bupivacaine for Pain Relief After Surgery

Completed · Phase 3 · Has a placebo group

Conditions studied: Post Operative Pain

In brief

This is a research study of SABER® -Bupivacaine, an experimental medication designed to reduce pain for up to 3 days after surgery. Given once by the surgeon at the end of surgery, SABER® - Bupivacaine delivers a locally-acting pain reliever directly to the surgical wound. The purpose of this study is to measure how well it works in reducing pain after laparoscopic cholecystectomy (surgery to remove the gall bladder) and to investigate the safety of SABER®-Bupivacaine (its side effects).

Key facts

Study ID

NCT02574520

Run by

Durect

People needed

399

Starts

2015-11-01

Expected to finish

2017-08-01

Last updated by the study team

2021-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients scheduled for elective outpatient laparoscopic cholecystectomy using a conventional 4-port laparoscopic procedure.
• Must be able and willing to provide written informed consent, complete trial-related procedures, and communicate with the trial staff.
• Males and females 18 years of age or older.
• ASA Class I, II, or III.
• Patients of child-bearing potential must agree to use a medically acceptable method of contraception to prevent pregnancy for the duration of their participation in the trial.
• Must be living close enough to the investigative site to attend the four scheduled follow-up clinic visits.

You may not qualify if…

• Pregnant or nursing females.
• Patients with absolute or relative contraindications to laparoscopic cholecystectomy.
• Patients with prior midline abdominal surgery who are at risk for adhesions that may complicate laparoscopic cholecystectomy and/or accurate pain assessments.
• Patients requiring emergency surgery or urgent surgery (fewer than 5 days between screening and surgery).
• Patients with a pre-planned overnight stay or pre-planned hospital admission.
• Patients scheduled for single incision, mini trocars, natural orifice transluminal endoscopic surgery (NOTES), robotic laparoscopic procedures, or any procedure (other than cholangiograms and minimal adhesiolysis) in addition to laparoscopic cholecystectomy.
• Patients with known hypersensitivity to amide local anesthetics such as bupivacaine.
• Patients with acute pain that is not due to cholecystitis.
• Patients with a history of chronic pain unrelated to gallbladder disease.
• Patients with ongoing depression or psychosis.
• Patients undergoing long-term treatment with opioids or other analgesics, including acetaminophen, NSAIDs, anticonvulsants (gabapentin or pregabalin), and antidepressants (SSRIs, SNRIs, and tricyclics), but not including daily low-dose aspirin.
• Patients who are being treated chronically with systemic corticosteroids or who will require peri-operative corticosteroids because of adrenal insufficiency (inhalational or topical corticosteroids are permitted).
• Patients who may be unsuitable for opioid administration (such as sensitivity [e.g., history of severe nausea and vomiting] hypersensitivity, known history of abuse or addiction, or unwillingness to take prescribed rescue opioids).
• Use of anticoagulants and antiplatelet drugs (with exception of low dose aspirin) in the 1 week prior to surgery.
• Patients who are incapable of operating the electronic diary.
• Patients participating in any other trial with an investigational drug or device concurrently or less than 30 days prior to surgery for this trial.
• Patients who, in the Investigator's opinion, should not participate in the trial or may not be capable of following the trial procedures for any reason.

Where it is running

• Durect Study Site 04 — Florence, Alabama, United States
• Durect Study Site 03 — Sheffield, Alabama, United States
• DURECT Study Site 24 — Arcadia, California, United States
• Durect Study Site 15 — Fontana, California, United States
• Durect Study Site 02 — Laguna Hills, California, United States
• Durect Study Site 18 — Laguna Hills, California, United States
• Durect Study Site 22 — Pensacola, Florida, United States
• Durect Study Site 12 — Indianapolis, Indiana, United States
• Durect Study Site 21 — Royal Oak, Michigan, United States
• Durect Study Site 17 — Jackson, Mississippi, United States
• Durect Study Site 16 — Las Vegas, Nevada, United States
• Durect Study Site 20 — Las Vegas, Nevada, United States
• Durect Study Site 05 — Stony Brook, New York, United States
• Durect Study Site 13 — Durham, North Carolina, United States
• Durect Study Site 09 — Cleveland, Ohio, United States
• Durect Study Site 11 — Cleveland, Ohio, United States
• Durect Study Site 07 — Cleveland, Ohio, United States
• Durect Study Site 14 — Philadelphia, Pennsylvania, United States
• Durect Study Site 08 — Houston, Texas, United States
• DURECT Study Site 01 — Houston, Texas, United States
• Durect Study Site 23 — Plano, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.